中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2013年
7期
27-29
,共3页
胃肿瘤%化学疗法,辅助%疗效研究
胃腫瘤%化學療法,輔助%療效研究
위종류%화학요법,보조%료효연구
Stomach neoplasms%Chemotherapy,adjuvant%Effectiveness studies
目的 探讨基于FOLFOX7或XELOX方案的新辅助化疗对胃癌的临床疗效,以期为其应用获得更多的临床证据.方法 回顾性分析2005年1月至2010年6月因胃癌行手术治疗患者的临床资料,根据化疗方法不同分为新辅助化疗组和传统化疗组,评价两组疗效、R0切除率及生存率.结果 共纳入行手术治疗的胃癌患者185例,其中新辅助化疗(FOLFOX7或XELOX方案)组113例,传统化疗组72例.两组一般资料比较差异无统计学意义(P＞0.05).新辅助化疗组化疗后完全缓解48例,部分缓解51例,疾病稳定14例,无疾病进展病例,有效率为87.6％ (99/113)；传统化疗组完全缓解30例,部分缓解25例,疾病稳定15例,疾病进展2例,有效率为76.4％(55/72),两组有效率比较差异有统计学意义(P＜0.05).新辅助化疗组R0切除率60.2％(68/113),显著优于传统化疗组的38.9％(28/72),差异有统计学意义(P＜ 0.01).两组术后生存率比较差异无统计学意义(P＞0.05).结论 新辅助化疗相对于传统化疗可提高R0切除率,但对提高术后生存率未见明显优势.
目的 探討基于FOLFOX7或XELOX方案的新輔助化療對胃癌的臨床療效,以期為其應用穫得更多的臨床證據.方法 迴顧性分析2005年1月至2010年6月因胃癌行手術治療患者的臨床資料,根據化療方法不同分為新輔助化療組和傳統化療組,評價兩組療效、R0切除率及生存率.結果 共納入行手術治療的胃癌患者185例,其中新輔助化療(FOLFOX7或XELOX方案)組113例,傳統化療組72例.兩組一般資料比較差異無統計學意義(P＞0.05).新輔助化療組化療後完全緩解48例,部分緩解51例,疾病穩定14例,無疾病進展病例,有效率為87.6％ (99/113)；傳統化療組完全緩解30例,部分緩解25例,疾病穩定15例,疾病進展2例,有效率為76.4％(55/72),兩組有效率比較差異有統計學意義(P＜0.05).新輔助化療組R0切除率60.2％(68/113),顯著優于傳統化療組的38.9％(28/72),差異有統計學意義(P＜ 0.01).兩組術後生存率比較差異無統計學意義(P＞0.05).結論 新輔助化療相對于傳統化療可提高R0切除率,但對提高術後生存率未見明顯優勢.
목적 탐토기우FOLFOX7혹XELOX방안적신보조화료대위암적림상료효,이기위기응용획득경다적림상증거.방법 회고성분석2005년1월지2010년6월인위암행수술치료환자적림상자료,근거화료방법불동분위신보조화료조화전통화료조,평개량조료효、R0절제솔급생존솔.결과 공납입행수술치료적위암환자185례,기중신보조화료(FOLFOX7혹XELOX방안)조113례,전통화료조72례.량조일반자료비교차이무통계학의의(P＞0.05).신보조화료조화료후완전완해48례,부분완해51례,질병은정14례,무질병진전병례,유효솔위87.6％ (99/113)；전통화료조완전완해30례,부분완해25례,질병은정15례,질병진전2례,유효솔위76.4％(55/72),량조유효솔비교차이유통계학의의(P＜0.05).신보조화료조R0절제솔60.2％(68/113),현저우우전통화료조적38.9％(28/72),차이유통계학의의(P＜ 0.01).량조술후생존솔비교차이무통계학의의(P＞0.05).결론 신보조화료상대우전통화료가제고R0절제솔,단대제고술후생존솔미견명현우세.
Objective To investigate the effect of neoadjuvant chemotherapy on gastric cancer based on FOLFOX7 or XELOX,so as to achieve evidence of clinical practice.Methods From January 2005 to June 2010,a retrospective analysis was performed for those patients with gastric cancer and underwent surgery.The patients were divided into neoadjuvant chemotherapy group and conventional chemotherapy group according to the chemotherapy method.The clinical efficacy,Ro resection rate and survival rate were evaluated in two groups.Results A total of 185 cases were included in neoadjuvant chemotherapy group (FOLFOX7 or XELOX,113 cases) and conventional chemotherapy group (72 cases).There was no significant difference in general status between two groups (P ＞ 0.05).Complete remission was in 48 cases,partial remission was in 51 cases,stable was in 14 cases,progression of disease was in 0 case in neoadjuvant chemotherapy group,and the effective rate was 87.6％ (99/113).Complete remission was in 30 cases,partial remission was in 25 cases,stable was in 15 cases,progression of disease was in 2 cases in conventional chemotherapy group,and the effective rate was 76.4％(55/72).There was significant difference in the effective rate between two groups (P＜ 0.05).The R0 resection rate in neoadjuvant chemotherapy group was higher than that in conventional chemotherapy group [60.2％ (68/113) vs.38.9％ (28/72)],and there was significant difference between two groups (P＜ 0.01).There was no significant difference in survival rate between two groups (P ＞ 0.05).Conclusion Neoadjuvant chemotherapy can reduce the tumor stage and improve the R0 resection rate,but has no obvious advantage in improving the survival rate during follow-up period.
